Evidence map›Paper›PMID 32544250›Full record

ArticleNucleic acids research2020

TFII-I-mediated polymerase pausing antagonizes GLI2 induction by TGFβ.

Angela L McCleary-Wheeler, Brooke D Paradise, Luciana L Almada, Annika J Carlson, David L Marks, Anne Vrabel, Renzo E Vera, Ashley N Sigafoos, Rachel L Olson, Martin E Fernandez-Zapico

Open access · goldAbstract read
In one paragraph

Article in Nucleic acids research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Nuclear Galectin-1 promotesProceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  3. Article
  4. PMHeliyon · 2024
    Article
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Angela L McCleary-WheelerSchulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
Brooke D ParadiseSchulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
Luciana L AlmadaSchulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
Annika J CarlsonSchulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
David L MarksSchulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
Anne VrabelSchulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
Renzo E VeraSchulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
Ashley N SigafoosSchulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
Rachel L OlsonSchulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
Martin E Fernandez-ZapicoSchulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
Mayo Clinic · US

Funding

Tissue CoreP50CA102701 · NCI · MAYO CLINIC ROCHESTER · PI PETERSEN, GLORIA M. · 2004 to 2018
$32.7M
PILOT AND FEASIBILTY PROGRAMP30DK084567 · NIDDK · MAYO CLINIC ROCHESTER · PI GREGORY J. GORES · 2009 to 2026
$22.2M
Mechanism of Pancreatic CarcinogenesisR01CA136526 · NCI · MAYO CLINIC ROCHESTER · PI FERNANDEZ-ZAPICO, MARTIN ERNESTO · 2009 to 2019
$3.0M
NCI NIH HHS P50 CA102701NCI NIH HHS R01 CA136526NIDDK NIH HHS P30 DK084567
6 · The paper itself

Abstract

The modulation of GLI2, an oncogenic transcription factor commonly upregulated in cancer, is in many cases not due to genetic defects, suggesting dysregulation through alternative mechanisms. The identity of these molecular events remains for the most part unknown. Here, we identified TFII-I as a novel repressor of GLI2 expression. Mapping experiments suggest that the INR region of the GLI2 promoter is necessary for GLI2 repression. ChIP studies showed that TFII-I binds to this INR. TFII-I knockdown decreased the binding of NELF-A, a component of the promoter-proximal pausing complex at this site, and enriched phosphorylated RNAPII serine 2 in the GLI2 gene body. Immunoprecipitation studies demonstrate TFII-I interaction with SPT5, another pausing complex component. TFII-I overexpression antagonized GLI2 induction by TGFβ, a known activator of GLI2 in cancer cells. TGFβ reduced endogenous TFII-I binding to the INR and increased RNAPII SerP2 in the gene body. We demonstrate that this regulatory mechanism is not exclusive of GLI2. TGFβ-induced genes CCR7, TGFβ1 and EGR3 showed similar decreased TFII-I and NELF-A INR binding and increased RNAPII SerP2 in the gene body post-TGFβ treatment. Together these results identify TFII-I as a novel repressor of a subset of TGFβ-responsive genes through the regulation of RNAPII pausing.

Indexed as

Hep G2 CellsHumansNuclear ProteinsPromoter Regions, GeneticRepressor ProteinsRNA Polymerase IITranscriptional ActivationTranscription Factors, TFIITranscription, GeneticTransforming Growth Factor betaZinc Finger Protein Gli2GLI2 protein, humanGTF2I protein, humanNuclear ProteinsRepressor ProteinsRNA Polymerase IITranscription Factors, TFIITransforming Growth Factor betaZinc Finger Protein Gli2

Identifiers

PMID32544250
PMCPMC7367210
OpenAlexW3034727010

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.